Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
You may also be interested in...
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.